Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026)

Jazz Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $11.7 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 2.22% year-over-year to $11.7 billion; the TTM figure through Mar 2026 stood at $11.7 billion (up 2.22% YoY), while the FY2025 annual figure was $11.5 billion, down 3.28% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $11.7 billion, up from $11.5 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $12.1 billion in Q3 2024, with the low at $10.3 billion in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $11.2 billion (2025), against an average of $11.3 billion.
• Peak annual rise in Total Non-Current Liabilities reached 75.09% in 2022, while the deepest fall reached 16.85% in 2022.
• Jazz Pharmaceuticals' Total Non-Current Liabilities stood at $10.7 billion in 2022, then grew by 5.42% to $11.3 billion in 2023, then advanced by 5.81% to $11.9 billion in 2024, then retreated by 3.28% to $11.5 billion in 2025, then grew by 1.41% to $11.7 billion in 2026.
• Business Quant data shows JAZZ's Total Non-Current Liabilities at $11.7 billion in Q1 2026, $11.5 billion in Q4 2025, and $11.2 billion in Q3 2025.